Ritu Lal

Dr. Ritu Lal, Ph.D., M.S. is the CEO and co-founder of GEn1E Lifesciences. She is a leader in Pharmaceutical R&D with 20+ years of experience in Biotech/Pharma companies. She has taken compounds from discovery to regulatory approval and has filed 15+ IND applications with the FDA in disease areas of neurology, inflammation, virology, pain and oncology. Two of these compounds have received New Drug Application (NDA) approvals from the FDA and Ministry of Health and Welfare, Japan (Kaletra® for the treatment of HIV and Horizant® (Regnite® in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN)). She has a doctorate in Pharmaceutical Sciences from the University of Maryland and a Master’s degree in Pharmacology from the University of Arizona. She has over 60 publications, book chapters and presentations. She is also a graduate of the Stanford University Graduate School of Business’ Master’s Degree in Management program.